Avenue Therapeutics to Participate in Upcoming Investor Conferences
September 03, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
April 23, 2024 08:09 ET
|
Sania Therapeutics
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting Abstracts outline an approach which is highly translatable,...
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 10, 2023 16:15 ET
|
Avenue Therapeutics
- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in...